1451 ET --Moderna Inc. is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Shares rose Wednesday after-hours on news of a Food and Drug Administration Breakthrough Therapy Designation for the combination of a cancer vaccine candidate and Merck & Co.'s Keytruda, but the stock declined after Moderna's Thursday earnings report. Revenue and earnings decreased amid lower demand for its Covid-19 vaccine. Sales fell 29%, to $5.1 billion. Cost of sales increased, reflecting factors including higher royalties and inventory write-offs. Moderna shares were recently down 7%, to $147.39. Dow Jones & Co. owns Factiva. (josh.beckerman@wsj.com)

(END) Dow Jones Newswires

February 23, 2023 15:06 ET (20:06 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Moderna.
Moderna (NASDAQ:MRNA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Moderna.